Protagonist Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Protagonist Therapeutics

05/05/2023 14:16

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 67 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 73 cents per share.
    * Reported revenue was zero​; analysts expected $2.00
million. 
    * The mean earnings estimate of analysts had fallen by
about 5.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Protagonist Therapeutics Inc shares had risen by 2.6% this
quarter and gained 116.3% so far this year.
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $35.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
5 at 01:16 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.73          -0.67          Beat
 Dec. 31 2022      -0.64          -0.69          Missed
 Sep. 30 2022      -0.87          -0.64          Beat
 Jun. 30 2022      -0.93          -0.84          Beat